The brand product, GlaxoSmithKline's antibiotic Augmentin ES-600, has annual sales of approximately $270 million.
Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) has announced that the US Food and Drug Administration has granted approval for the company's ANDA (abbreviated new drug application) for Amoxicillin/Clavulanate Potassium For Oral Suspension, 600 mg/42.9 mg/5 mL. A launch date has not yet been finalized.
Teva's Amoxicillin/Clavulanate Potassium FOS, 600 mg/42.9 mg/5 mL is the AB-rated generic equivalent of GlaxoSmithKline's antibiotic Augmentin ES-600.
According to Teva, the brand product has annual sales of approximately $270 million.
Published by Globes [online] - www.globes.co.il - on March 14, 2004